Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

eWall for Active Long Living

eWALL

Independent living of senior citizens is one of the main challenges linked to the ageing population, due to the impact on: (a) the life of the elderly people, (b) the national health systems, (c) the insurance companies, (d) the relatives and (e) the care-givers. Senior citizens may suffer from a number of diseases, including the decline in...

Funding Programme
EU-FP7
Start Date
End Date
Total Funding
€ 8 838 005

Joint Action on Dementia 2015-2018

Joint Action on Dementia 2015-2018. The Joint Action will focus on two phases on work: approximately 12 months on developing a consensus on the best evidence of effective action in 4 key areas (diagnosis and post-diagnostic support; crisis and care coordination; quality of care in residential care settings; and dementia-friendly communities); and...

Funding Programme
EU health
Start Date
End Date
Total Funding
€ 1 498 710

SUstainable PROduction of GALanthamine by both in vitro and agricultural crops of highly galanthamine-containing plants

SUPROGAL

Galanthamine is an alkaloid produced exclusively by plants of the family Amaryllidaceae, mainly belonging to the genus Galanthus, Leucojum and Narcissus. Owing to its acetylcholinesterase inhibitory activity, galanthamine is used and marketed for the treatment of the Alzheimer’s disease, among others. Although it is obtained by organic synthesis...

Funding Programme
EU-FP7
Start Date
End Date
Total Funding
€ 1 343 680
European Countries Involved

VELES Excellence Hub - Strengthening the South-East Europe Smart Health Regional Excellence and Boosting the Innovation Potential

VELES

Smart Health is EU Strategic Value Chain that contributes to growth, jobs and competitiveness. Health Data is the main enabler for the value chain, but it also depends on cutting edge technologies - AI, cloud computing, IoT, to integrate the dispersed knowledge and support innovative healthcare solutions and services. EC sets the creation of a...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 4 750 000
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).